Several human cancers have been identified that feature mutations in the kinase domain of TLK1 [58–62], and high TLK1 expression levels correlate with radioresistance [63,64] thus raising the possibility that TLK1 is an oncogene and potential therapeutic target. The gene discussed is TLK1; the disease is cancer.